News

HKBU Signed a MoU with CR Jiangzhong and China Resources Research Institute of Science & Technology

7 Dec, 2022

HKBU signed a Memorandum of Understanding (MoU) with CR Jiangzhong and China Resources Research Institute of Science & Technology to reach an understanding on the research of shenlingcao (參靈草) for treating post Covid-19 syndrome.

The signing ceremony was taken place at the campus on 7 December 2022, signed by Professor Terence Lau, Interim Chief Innovation Officer of HKBU, Mr. Zhi Zhe, Vice President of China Resources Research Institute of Science & Technology and Mr. Liu Wenjun, General Manager, R&D, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. It was well attended by Mr. Bai Xiaosong, CEO, China Resources Pharmaceutical Group Ltd, Mr. Yu Shunyan, Chairman, China Resources Double-Crane Pharmaceutical Co., Ltd. and Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) of HKBU.

Professor Bian gave an overview on School of Chinese Medicine and the recent technology development and achievement of Chinese medicine at HKBU, while Mr. Bai and Mr. Yu shared the R&D development and signature products of China Resources Pharmaceutical Group. Riding on both parties’ competitive advantages, they expected to explore more collaboration opportunities in advancing technologies development and incubation in Chinese medicine.